199 results on '"Masetti C"'
Search Results
2. T.07.4: ACTIVE HCV OR HBV INFECTION DOES NOT IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
3. Myosteatosis is not associated with complications or survival in HCC patients undergoing transarterial embolization
4. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction
5. Prevalence and predictiors of porto-sinusoidal vascular disorder in patients with constantly elevated gamma-glutamyl transferase levels: A multicenter Italian study
6. OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION
7. A different perspective on sofosbuvir‐ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital‐c network study
8. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C
9. High rates of histological findings compatible with porto-sinusoidal vascular liver disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy
10. Severe osteolysis and soft tissue mass around total hip arthroplasty: Description of four cases and review of the literature with respect to clinico-radiographic and pathologic differential diagnosis
11. High prevalence of multiple drug resistant bacterial infections in patients with pyogenic liver abscesses following loco regional therapy for liver cancer
12. No impact of the 2020 COVID-19 lockdown on hospitalization rates for alcoholic liver disease in a large tertiary hospital in Milan
13. T.12.1: IDENTIFICATION OF KEY PREDICTORS OF SIGNIFICANT WEIGHT LOSS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) PATIENTS: A MULTICENTRE STUDY.
14. Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications
15. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
16. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018
17. Natural Regeneration of a Stone Pine (Pinus Pinea L.) Wood in the 'Maremma Nature Park' (Grosseto, Italy)
18. Yearly water balance of the Piedmont Alpine zone
19. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
20. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
21. Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: results from a multicenter study
22. MODELLI 3D E DATI GIS: UNA LORO INTEGRAZIONE PER LO STUDIO E LA VALORIZZAZIONE DEI BENI CULTURALI.
23. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?
24. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
25. Effect of solar radiation deprival on selected parameters of peach fruits
26. Low cost sensors to measure solar radiation in woody plant communities
27. Modifications of some characteristics in nectarine fruit induced by light deprivai at different times of fruit growth
28. Light environment at harvest in two nectarine planting systems
29. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study
30. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
31. Natural HCV resistance is common in Italy and differently associated to genotypes
32. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
33. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease
34. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
35. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
36. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens
37. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?
38. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease
39. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
40. Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting
41. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus-infected patients treated with recommended regimens
42. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study
43. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?
44. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting
45. Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting
46. Clinical and Functional Changes Associated with the Achievement of Sustained Response in HCV Genotype-1 Infected Liver Transplant Recipients: Does Sofosbuvir Differ from Peg-Interferon Therapy?
47. Cryptogenic cirrhosis is associated with cardiometabolic and oncologic comorbidities and poor liver-related prognosis
48. FRI-379 - Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
49. THU-387 - On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?
50. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.